Literature DB >> 3965596

Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses.

T Sonoguchi, H Naito, M Hara, Y Takeuchi, H Fukumi.   

Abstract

A total of 663 pupils at four schools were studied serologically and clinically during a period of large sequential and/or mixed epidemics of infection with two subtypes of influenza A virus, H3N2 and H1N1. Of 91 middle-school pupils infected with H3N2 virus shortly before and 82 pupils not previously infected with this subtype, 59% and 91% became infected with H1N1 virus, respectively; this difference was significant. Similar results were obtained at the two primary schools studied. At a high school where epidemics due to the H3N2 and H1N1 subtypes occurred concurrently, the rate of infection of individual pupils with both viruses (2%) was significantly lower than those at the other three schools (21%, 23%, and 31%, respectively), where an epidemic caused by the H3N2 subtype appeared first and was then partially overlapped and succeeded by an epidemic caused by the H1N1 subtype. These findings suggest the existence of cross-subtype protection in humans during sequential and/or concurrent epidemics caused by two viral subtypes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3965596     DOI: 10.1093/infdis/151.1.81

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  62 in total

Review 1.  Immunity to influenza: the challenges of protecting an aging population.

Authors:  Jacqueline M Katz; Julie Plowden; Mary Renshaw-Hoelscher; Xiuhua Lu; Terrence M Tumpey; Suryaprakash Sambhara
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Epitope specific T-cell responses against influenza A in a healthy population.

Authors:  Miloje Savic; Jennifer L Dembinski; Yohan Kim; Gro Tunheim; Rebecca J Cox; Fredrik Oftung; Bjoern Peters; Siri Mjaaland
Journal:  Immunology       Date:  2015-12-08       Impact factor: 7.397

3.  Population effect of influenza vaccination under co-circulation of non-vaccine variants and the case for a bivalent A/H3N2 vaccine component.

Authors:  Colin J Worby; Jacco Wallinga; Marc Lipsitch; Edward Goldstein
Journal:  Epidemics       Date:  2017-02-21       Impact factor: 4.396

4.  B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms.

Authors:  Javier Rangel-Moreno; Damian M Carragher; Ravi S Misra; Kim Kusser; Louise Hartson; Amy Moquin; Frances E Lund; Troy D Randall
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

Review 5.  Evolution and ecology of influenza A viruses.

Authors:  R G Webster; W J Bean; O T Gorman; T M Chambers; Y Kawaoka
Journal:  Microbiol Rev       Date:  1992-03

6.  Cross-protection between successive waves of the 1918-1919 influenza pandemic: epidemiological evidence from US Army camps and from Britain.

Authors:  John M Barry; Cécile Viboud; Lone Simonsen
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

Review 7.  Heterosubtypic immunity to influenza A virus: where do we stand?

Authors:  Kristie M Grebe; Jonathan W Yewdell; Jack R Bennink
Journal:  Microbes Infect       Date:  2008-07-09       Impact factor: 2.700

8.  Prior immunity helps to explain wave-like behaviour of pandemic influenza in 1918-9.

Authors:  John D Mathews; Emma S McBryde; Jodie McVernon; Paul K Pallaghy; James M McCaw
Journal:  BMC Infect Dis       Date:  2010-05-25       Impact factor: 3.090

9.  Controlling influenza by cytotoxic T-cells: calling for help from destroyers.

Authors:  Michael Schotsaert; Lorena Itatí Ibañez; Walter Fiers; Xavier Saelens
Journal:  J Biomed Biotechnol       Date:  2010-05-24

10.  DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

Authors:  Suzanne L Epstein; Terrence M Tumpey; Julia A Misplon; Chia-Yun Lo; Lynn A Cooper; Kanta Subbarao; Mary Renshaw; Suryaprakash Sambhara; Jacqueline M Katz
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.